Cardiff Oncology, Inc.
Cardiff Oncology, Inc.（CRDF）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
crdf · 股价预测 · 14 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 14 位华尔街分析师
Buy
14 位分析师
共识
评级分布
12 个月目标价
High
$2.00
Consensus
$2.00
+33.3% upside
Low
$2.00
Median: $2 · Last Close: $1.50
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Bear算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.42 | ↓ 5.00% |
1-day model range: $1.4–$1.45. Peak: $1.45 (-5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -46.1% |
| 2028 | $1 | -58.6% |
| 2029 | $1 | -63.3% |
| 2030 | $1 | -65.5% |
| 2031 | — | -66.5% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRDF · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | Craig-Hallum | Downgrade ↓ | Buy→Hold |
| 2026-06-01 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-06-01 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2026-02-25 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-01-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cardiff Oncology, Inc. (CRDF) stock. Of the recent 51 rating actions, 2 were upgrades and 10 were downgrades. 14 analysts currently cover CRDF.
分析师推荐趋势
CRDF analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$0M
↑ 6.1% YoY
Revenue Next Year
$0M
↓ 22.4% YoY
EPS This Year
$-0.68
EPS Next Year
$-0.82
↑ 20.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRDF EPS of $-0.68 for the current fiscal year, based on estimates from 6 analysts. The CRDF revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CRDF 股价预测由两类独立数据源支撑：来自 14 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CRDF 的共识目标价为 $2.00（+33.3% 上行空间），分析师共识为 Buy。
CRDF 的短期预测（明日）为 $1.42（-5.00%）。 CRDF 对 2027 年的股价预测均值为 $1。 CRDF 对 2030 年的预测区间为 $0–$1。
Cardiff Oncology, Inc. 在 NASDAQ 上市，代码 CRDF。CRDF 在 2027 年的整体展望偏积极，在覆盖分析师中约 50% 对应 Buy 共识。
常见问题
CRDF 预测 · 8 个问题根据 14 位华尔街分析师，CRDF 的 12 个月平均目标价为 $2.00，最高 $2.00、最低 $2.00。若有图表，中位目标价可在上方查看。相对当前价 $1.50，隐含约 +33.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.